Vice President, Access, Value Evidence & Pricing

Overview Create a future where DNA is no longer destiny. Join Rocket Pharma. Rocket Pharma is a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases. We are a team of creative, compassionate, and driven individuals united by a profound mission of seeking genetic medicine cures. Rocket places tremendous value on our people and fosters a collaborative environment where bold ideas thrive and every team member makes a meaningful impact. Our core values guide everything we do: we trust one another, show generosity toward patients, embrace curiosity, and strive to elevate science. Team members receive a competitive total rewards package, including equity participation, 401(k) matching, and excellent health benefits. Position Summary The Vice President, Access, Value Evidence & Pricing, is responsible for shaping the global value, pricing, reimbursement, evidence, and patient access strategy for the company's portfolio of gene therapies. Reporting to the Chief Commercialization Officer, this leader will build and lead an integrated value, access, and pricing function spanning U.S. payer strategy, reimbursement strategy, HEOR and evidence generation, access policy, international access, trade and channel strategy, patient services, and payer access to genetic testing for genetic cardiomyopathies. This leader will ensure that value, pricing, and access strategy is developed with a clear understanding of payer coverage requirements, genetic testing access barriers, country-level reimbursement requirements, international reference pricing dynamics, launch sequencing considerations, and evidence needs across priority markets. Responsibilities Enterprise Value, Access, and Pricing Strategy Serve as Rocket's senior leader for value, pricing, and patient access strategy. Represent global value, access & pricing perspective, partnering with Global Product Heads and cross-functional leaders to drive access strategy, evidence planning, launch sequencing, and lifecycle decision-making from early development through commercialization. Provide strategic input into portfolio prioritization, business planning, launch readiness, and external communications by translating payer, HTA, policy, pricing, reimbursement, diagnostic access, and access dynamics into enterprise-level recommendations. Partner with the Chief Commercialization Officer, Executive Leadership Team, and other senior stakeholders to assess access opportunities, reimbursement risks, pricing considerations, evidence needs, diagnostic access requirements, and advice on long-term access outlook for Rocket's portfolio. Develop and maintain enterprise-level access readiness dashboards and KPIs spanning payer access, reimbursement outcomes, patient access performance, treatment center access barriers, genetic testing coverage and pull-through, pricing assumptions, and pull-through effectiveness. Global Market Access and Pricing Strategy Develop and execute Rocket's integrated global pricing and market access strategy across U.S. commercial and government payers, international markets and access archetypes, HTA bodies, ensuring sustainable patient access and commercial viability. Anticipate, monitor and translate emerging international access and policy frameworks and development, international reference pricing dynamics, diagnostic testing coverage trends, and gene therapy-specific payment models, into enterprise portfolio and launch strategy. U.S. Market Access, Pricing, Reimbursement, and Channel Strategy Lead U.S. market access, pricing, and reimbursement strategy across commercial and government payers, IDNs, launch pricing, gross-to-net assumptions, and innovative access models. Translate U.S. healthcare policy, payer management, diagnostic testing coverage, site-of-care dynamics, and gene therapy payment trends into portfolio strategy, launch planning, and genetic testing access pathways for genetic cardiomyopathies. Treatment Center Enablement, Patient Services, Trade, Distribution and Channel Strategy Partner with cross-functional launch team to shape US treatment center selection strategy. Lead U.S. treatment center readiness for patient services, HUB operations, genetic testing access resources, and trade, distribution, and channel strategy to ensure payer, reimbursement, patient support, and operational requirements are embedded into launch readiness and sustained across the product lifecycle. Health Economics and Outcomes Research Lead Rocket’s HEOR, evidence generation, and value demonstration strategy across the portfolio to support payer decision-making, HTA and reimbursement requirements, genetic testing access, clinical development planning, evidence packages, publications, payer communications, and regulatory and post-approval evidence strategy. Organizational Leadership, Governance, Capability Building Build, lead, and scale a high-performing value, access, and pricing organization with the talent, governance, processes, capabilities, culture, and compliance standards needed to support Rocket’s growing portfolio and enterprise objectives. Access policy shaping and external engagement Shape access policy and external engagement by building senior relationships with payers, HTA and reimbursement authorities, policy stakeholders, treatment centers, advocacy organizations, channel partners, and industry coalitions to advance sustainable access to cell and gene therapies. Qualifications Bachelor’s degree required. Advanced degree (MBA, PharmD, PhD, MD, MPH) strongly preferred; significant gene therapy expertise may be considered in lieu of a specific degree requirement. 15+ years of progressive commercial leadership experience in biopharmaceuticals, with demonstrated expertise spanning market access, pricing, HEOR, and patient access in large and emerging company environments. Demonstrated experience